Gastric cancer is the fifth most common cancer worldwide and associated with a poor prognosis and about 740,000 deaths per year.^1,2 The 5-year overall survival is around 25% but varies greatly depending on the tumor stage (TNM) and histology. In particular, signet-ring histology is associated with dismal prognosis.³ Surgery with lymph node dissection is the primary treatment for medically fit patients with resectable tumors.⁴ Perioperative chemotherapy is recommended following curative (R0) resection. The recurrence rate is high after frontline multimodal therapy for 40–80% of the patients.^5,6 The median survival of patients with unresectable gastric cancer treated with systemic chemotherapy is not greater than 12 months.⁷ Among such patients, the median survival of those with peritoneal metastasis (PM) was reported to be even worse at 6–10 months.⁸ Therefore, National Comprehensive Cancer Network Guidelines for Gastric Cancer encourages patients with gastric cancer to participate in well-designed clinical trials investigating novel therapeutic strategies to enable further advances.⁴

中文翻译：

---

低剂量顺铂和多柔比星 (PIPAC C/D) 腹腔内加压气溶胶化疗治疗胃癌和腹膜转移：一项 II 期研究

胃癌是全球第五大最常见的癌症，预后不良，每年约有 740,000 人死亡。^1,2 5 年总生存率约为 25%，但因肿瘤分期 (TNM) 和组织学而异。特别是，印戒组织学与预后不良有关。³手术结合淋巴结清扫是可切除肿瘤患者的主要治疗方法。⁴建议在根治性 (R0) 切除后进行围手术期化疗。40-80% 的患者在一线多模式治疗后复发率很高。^5,6接受全身化疗的不可切除胃癌患者的中位生存期不超过 12 个月。⁷在这些患者中，据报道腹膜转移 (PM) 患者的中位生存期更差，为 6-10 个月。⁸因此，国家综合癌症网络胃癌指南鼓励胃癌患者参与精心设计的临床试验，研究新的治疗策略，以取得进一步进展。⁴